



Consultation on the Strategic roadmap for EU-CELAC Joint Initiative on Health Research and Innovation

- Madrid Consultation and Validation Workshop – October 2014



Remote consultation



Objective:

Explore the extent to which policy makers and funders of health research in EU and LAC agree with the proposed **Strategic roadmap for EU-CELAC Joint Initiative on Health Research and Innovation**

Identification of policy makers and funders of health research to be consulted:

EU-LAC Health stakeholder database developed by Mincyt - Argentina, updated with the help of partners and advisory board



Remote consultation




Consultation:

- Stakeholders were contacted by e-mail and invited to answer a questionnaire: vision and mission, objectives and principles, governance structure
- Also tried to map the stakeholders interested in further discussing the initiative
- ISCIII sent the questionnaires to EU and Fiocruz to LAC - with the help of partners and advisory board
- A spanish version was provided to the LA spanish speaking countries



EU
n=19



EU respondents



Country	Institution
Sweden	Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)
Cyprus	Research Promotion Foundation
Romania	Executive Agency for Higher Education, Research, Development and Innovation Funding
Estonia	Estonian Research Council
Slovakia	Ministry of Education, Science, Research and Sport of the Slovak Republic
Finland	Academy of Finland
Finland	VTT
The Netherlands	ZonMw
Latvia	Study and Res Administration, MoES
Belgium	Belgian Science Policy Office
Hungary	Hungarian Scientific Research Fund (OTKA)
Germany	BMBF
France	French National Research Agency (ANR)
Austria	Austrian Science Fund
Poland	Ministry of Science and Higher Education
Greece	Hellenic Pasteur Institute
Czech Republic	Minister of Education, Youth and Sports
Spain	Instituto de Salud Carlos III
Italy	Istituto Superiore di Sanita' (ISS)

EU-LAC HEALTH has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 281459.





LAC
n=23




LAC respondents



País	Institución
Chile	1. Universidad Católica de la Santísima Concepción 2. Dirección Servicio de Salud Talcahuano
Chile	Pontificia Universidad Católica de Chile
Uruguay	Ministerio de Salud Pública
Peru	Instituto Nacional de Salud
Costa Rica	CENDEISSS CCSS
Costa Rica	Universidad de Costa Rica
Costa Rica	Ministry of Science, Technology and Telecommunications
Costa Rica	Ministerio de Ciencia, tecnología y Telecomunicaciones (MICITT)
Mexico	National Council for Science and Technology - CONACYT Mexico
Argentina	Universidad Isalud
Argentina	Comision Nacional Salud Investiga. MINISTERIO DE SALUD
Argentina	IN Cancer
Argentina	CONICET
Argentina	CONICET
Panama	Instituto Conmemorativo Gorgas de Estudios de la Salud
Panama	Caja de seguro social
Panamá	Universidad Santa María la Antigua
Trinidad and Tobago	NIHERST
Trinidad and Tobago	Caribbean Public Health Agency
Barbados	Caribbean Science Foundation
Brazil	M. of Health
Brazil	FIOCRUZ
Jamaica	Tropical Medicine Research Institute, University of the West Indies



Vision and Mission



Vision: to be the reference in the field of the bi-regional health research collaboration between EU and LAC, including the EU as a whole and each country individually, involving LAC countries and considering their diversity, engaged with and providing support to different political agendas such as health research and innovation, and development cooperation, among others.

Mission: to implement a sustainable and long-term collaborative health research effort between policy makers, researchers and stakeholders from EU and LAC directed to improving the health and social wellbeing of citizens, contributing to reach a better quality of life.





Do you agree that these should be the vision and mission of EU- CELAC JIHRI?



EU

LAC



- LAC:** No: without a detailed organization and funding schemes it is not possible to judge
No: *public policy* instead of *political agenda* (programas políticos)
- EU:** No: vision and mission could be more specific and more ambitious



Relevance of the proposed objectives



Objectives	EU				LAC			
	None	Low	Med.	High	None	Low	Med.	High
Addressing common challenges, aligning research programmes and avoiding duplications		1	5	13	1		5	17
		5%	26%	68%	4%		22%	74%
Maximizing synergies by putting together expertise scattered across different countries			4	15	1		2	20
			21%	79%	4%		9%	87%
Expanding the scientific and societal impact of the research, thus reducing health gaps in a globalized world			6	13			4	19
			32%	68%			17%	83%

Other suggested objectives



- Promote health research scientific cooperation between EU and LAC
- Support priority health research not easily financed by other sources
- Promote human resources development through academic mobility and internships
- Promote capacity building in research policy for countries authorities and in methodological and organizational issues for researchers
- Promote access to information and knowledge / promote the sharing of information and knowledge
- Normalize information standards in order to meet international criteria that help integrate data relevant to common health issues



Relevance of the proposed principles (%)



Principles	EU					LAC				
	None	Low	Med.	High	N.A.	None	Low	Med.	High	N.A.
Jointly defined strategic research agenda tackling global challenges		5	32	63				35	65	
Improved integration of national and regional activities through existing or innovative funding schemes	5	5	32	58		4		35	61	
Co-responsibility, co-ownership and inclusiveness		16	32	42	11			35	65	
Flexibility to allow reacting to the changing landscape		5	42	47	5		4	9	87	
Enhanced availability for accessibility and delivery of efficacious medical products and health care services	5	11	16	68			9	39	43	9
Sound operational strategy		5	42	42	11		4	22	74	
Transparency, accountability and visibility of the initiative		5	16	79			4	9	87	

Other suggested principles



- Work at the highest standard of ethics
- All projects envisioned or undertaken must have a balance of benefits for all parties involved. To ensure this, there must be fair and balanced representation of small and middle-income countries
- Develop and enhance capacity in health research with particular reference to countries that are lagging scientifically and in need of capacity building
- Encourage bilateral collaboration and the sharing and transfer of information, knowledge and skills among key institutions and groups



Proposed governance structure



EU-CELAC SOM

GOVERNING BOARD

Representatives from EU-CELAC health research and innovation funding agencies and multinational institutions

SCIENTIFIC ADVISORY BOARD

Working Group 1

Working Group 2

Working Group 3

Working Group 4

Working Group 5

Working Group 6

**SECRETARIAT
(Management)**

**EU-LAC Health
Consortium**



STAKEHOLDER ADVISORY BOARD

Health Authorities

Scientific Associations

Regional Organizations


Product Development Partnerships

Other Stakeholders


Scientific Objectives of the **Joint Initiative on Health Research and Innovation**




Does this structure meet the objectives, principles and key elements for a good governance of the initiative?




EU



LAC



Does this structure meet the objectives, principles and key elements for a good governance of the initiative?



YES


- This kind of structure of governance is common in Europe and it usually works
- It will help if the research priorities were defined

NEED MORE INFORMATION

- Decision making is concentrated in the GB but it is not clear how countries will participate in this board
- Structure seems fine, however the way to finance this needs further discussion
- It is not clear if there are minimum conditions
- How is the exchange/consensus between Stakeholders and Scientists Board envisaged?
- How would the researchers be nominated to the Scientific Board?



Does this structure meet the objectives, principles and key elements for a good governance of the initiative?




TAKE CARE

- In the scheme provided, the Stakeholder Board also includes scientific associations – be careful not to have those associations represented twice, via the Scientific Board
- Experts from small countries with a fledgling capacity in research may be at a disadvantage -their voice is important in defining the research agenda so it meets the needs of their populations and ensures balance of interests and representation
- Take care when sitting together industry and government – this maybe difficult for certain countries



Does this structure meet the objectives, principles and key elements for a good governance of the initiative?



SUGGESTIONS


- Membership of the GB should be rotated and limited to a 2-year term in order that there be more participation, broader based representation and equity on this body
- All projects envisioned or undertaken must have a balance of benefits for all parties involved. To ensure this, there must be fair and balanced representation of small and middle-income countries
- The GB should include a representative from the Scientific Board and one from the Stakeholders Board, selected by members of each group
- The Scientific Board should include a working group on the Ethical and Legal Issues
- Special attention should be given to patient association being included in the Stakeholders Board in the org chart




Would your institution be interested in being part of this joint initiative?




EU




LAC




Would your organization be interested in discussing further this initiative with the EU-LAC Health Consortium?



EU



LAC



Would your organization be interested in discussing further this initiative with the EU-LAC Health Consortium?



MAYBE:

Due to limited resources we are not sure about our abilities

YES:

To be active in the priority definition discussion

YES, to discuss further:


- Membership
- Legal form
- Funding issues
- Suggestion of other priorities / other prioritization criteria (ex: availability of resources)




Would you like to continue receiving information on the initiative or the project?



EU



LAC



Would you like to comment any other aspect not reflected in the questionnaire?




- Importance of promoting access to scientific information
- Importance of promoting research quality
- In order to have more interest from stakeholders, EU-LAC should have meetings in the regions?



EU-LAC Health Partners




Dr. Rafael de Andrés (Coordinator)
ISCIH, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain



Dr. Stephanie Splett-Rudolph
DLR, Deutsches Zentrum für Luft- und Raumfahrt e.V., Germany



Dr. Luis Tacsan Chen
RIMAIS, Red Iberoamericana Ministerial de Aprendizaje e Investigación en Salud, Ministerio de Salud, Costa Rica



Dr. Paulo Buss
FIOCRUZ, Fundação Oswaldo Cruz, Brazil



Dr. Joaquin Guinea
INNOVATEC, Sociedad para el Fomento de la Innovación Tecnológica, Spain



Eng. Águeda Menvielle
MINCYT, Ministerio de Ciencia, Tecnología Argentina e Innovación Productiva

The COHRED Group



Dr. Najia Musolino
COHRED, Council on Health Research for Development, Switzerland /Mexico



Dr. Diassina Di Maggio
APRE, Agenzia per la Promozione della Ricerca, Italy

